Tiragolumab Combo Improves PFS/OS Vs Chemo in Esophageal Cancer
January 20th 2024Data from the phase 3 SKYSCRAPER-08 trial may support tiragolumab plus atezolizumab and chemotherapy as an alternative frontline treatment option for those with locally advanced or metastatic esophageal squamous cell carcinoma.
Dato-DXd Improves PFS Vs Chemo in HR+/HER2– Metastatic Breast Cancer
December 8th 2023Data from the phase 3 TROPION-Breast01 trial support datopotamab deruxtecan as a potential treatment option for patients with endocrine-resistant, hormone receptor–positive, metastatic breast cancer, says Aditya Bardia, MD, MPH.
Pomalidomide Combo Yields PFS/OS Benefits in R/R Multiple Myeloma
October 1st 2023Pomalidomide plus bortezomib and dexamethasone confers a larger progression-free survival benefit than bortezombib plus dexamethasone among patients with relapsed/refractory multiple myeloma in the phase 3 OPTIMISMM trial.
Ribociclib/Endocrine Therapy Improves iDFS in HR+/HER2– Breast Cancer
June 2nd 2023Results from the phase 3 NATALEE trial investigating ribociclib plus endocrine therapy may change practice for the treatment of hormone receptor–positive or HER2-negative early breast cancer, according to an expert from the University of Chicago Medicine.
Efficacy of Naporafenib in NRAS-Mutant Unresectable/Metastatic Melanoma Presented at 2022 ESMO
September 10th 2022Results of a phase 2 trial show favorable efficacy and tolerable safety of naporafenib in combination with rineterkib, trametinib, or ribociclib in previously treated, unresectable or metastatic melanoma.